Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CCR3 | P51677 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21682973 | 0.83 | SLC6A3 (1.00) | SLC6A3MAPTFOLH1KMT2APOLB | |
| SCHEMBL26804101 | 0.83 | SLC6A3 (0.78) | SLC6A3FOLH1KMT2AALDH1A1 | |
| SCHEMBL26804142 | 0.83 | SLC6A3 (0.67) | SLC6A3FOLH1ALDH1A1 | |
| SCHEMBL26804134 | 0.83 | SLC6A3 (0.78) | SLC6A3MAPTLMNAFOLH1KMT2A | |
| SCHEMBL26804140 | 0.81 | SLC6A3 (0.72) | SLC6A3MAPK1LMNASMN1; SMN2HTT | |
| SCHEMBL2431422 | 0.81 | CASR (0.69) | MAPTKMT2AHTTPOLBMEN1 | |
| SCHEMBL4637913 | 0.78 | CNR1 (0.77) | MAPTMAPK1LMNASMN1; SMN2CCR3 | |
| SCHEMBL27182963 | 0.76 | HTT (0.63) | MAPTMAPK1LMNASMN1; SMN2KMT2A | |
| SCHEMBL27929224 | 0.76 | HTT (0.66) | MAPTMAPK1LMNASMN1; SMN2KMT2A | |
| SCHEMBL26804115 | 0.76 | SLC6A3 (0.82) | SLC6A3MAPTSMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TFEB, TP53, BECN1 | SLC6A3 2908/4885MAPT 416/4885MAPK1 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.